Compare Adaptive Biotechnologies Corp (ADPT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Regeneron Pharmaceuticals Inc trades at $665.54 (market cap $70.90B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 21.3× Adaptive Biotechnologies Corp's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | REGN | |
|---|---|---|
Market Cap | $3.33B | $70.90B |
Sector | Health | Health |
52-Week High | $22.37 | $812.27 |
52-Week Low | $10.24 | $542.52 |
Enterprise Value | $3.19B | $64.85B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Regeneron (REGN) trades at $676.23, up 3.36% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $9.47 exceeding the $8.91 forecast. Revenue grew to $14.34B in 2025, with a net income margin of 29.65%. Recent FDA acceptance of cemdisiran for gMG and inclusion in a manufacturing review pilot program highlight positive regulatory developments.
Outlook remains positive given earnings momentum and analyst consensus, but risks include regulatory scrutiny and competitive pressures. The consensus price target of $778.29 implies 15% upside, supported by 32 buy ratings and no sells. However, legal investigations and reliance on key drug portfolios warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
